Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026
BMRA vs LNTH: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
LNTH Wins Head-to-Head Institutional Verdict (6–0 across 6 Pillars · 9–1 Matrix Metrics)
LNTH Overall Winner
6-Pillar Tally: BMRA 0 – 6 LNTH
Matrix Metrics: BMRA 1 – 9 LNTH
As of Nov 16, 2026, Lantheus Holdings, Inc (LNTH) is the stronger overall head-to-head candidate over Biomerica Inc (BMRA) in the Tradestie Institutional Equity Comparison Engine, winning 9–1 core matrix metrics and 6–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). BMRA carries a Unified Composite Score of 44.5/100 (HOLD) at $1.36 (N/M Forward P/E, -125.2% operating margin), whereas LNTH carries 43.5/100 (HOLD) at $101.75 (15.4x Forward P/E, 16.9% operating margin).
- Composite vs. Pillar Nuance: While BMRA currently prints a higher short-term Unified Composite Score (44.5/100 HOLD vs. LNTH 43.5/100 HOLD), LNTH captures the overall institutional head-to-head verdict (9–1 matrix metrics and 6–0 across the 6 pillars) due to superior fundamental profitability (16.9% vs. -125.2% operating margin) and revenue trajectory (+1.5% vs. -8.3% YoY).
- Technical & Structure Timing Caution: BMRA is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 28.0); meanwhile LNTH trades in a Neutral technical trend (CONSOLIDATION options phase, RSI 65.8). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Executive Snapshot Side-by-Side Composite Ratings & Technical Regime
Ask Alpha AI About BMRA vs LNTH
BMRA
Biomerica Inc
$1.36
+0.0% 1D
Market Cap
$6.0M
TTM Revenue
$4.3M
Forward P/E
N/M
Beta / 30D Vol
0.67β · 62% Vol
Unified Composite Score
44.5
HOLD
Tech 40.0
Fund 47.0
Flow 50.0
Mom 44.0
Weinstein Technical Phase
Markdown · Sell / avoid
LNTH
Head-to-Head Winner
Lantheus Holdings, Inc
$101.75
+0.15% 1D
Market Cap
$6.6B
TTM Revenue
$1.56B
Forward P/E
15.4x
Beta / 30D Vol
0.45β · 5% Vol
Unified Composite Score
43.5
HOLD
Tech 42.0
Fund 49.0
Flow 58.0
Mom 50.0
Weinstein Technical Phase
Neutral · Hold
6-Pillar Scorecard Institutional Category Breakdown (BMRA 0 – 6 LNTH)
1. Valuation Multiples
LNTH
Forward P/E
N/M
15.4x
Trailing P/E
N/M
25.3x
PEG Ratio
N/M
0.61x
EV / Revenue
1.1x
4.2x
2. Growth & Scale
LNTH
Revenue Growth (YoY)
-8.3%
+1.5%
Earnings Growth (YoY)
+0.0%
-19.5%
TTM Revenue (USD)
$4.3M
$1.56B
Market Cap
$6.0M
$6.6B
3. Profitability & Quality
LNTH
Gross Margin
0.9%
61.3%
Operating Margin
-125.2%
16.9%
Net Profit Margin
-115.5%
17.3%
Return on Equity (ROE)
-113.8%
21.8%
4. Balance Sheet & Cash Flow
LNTH
Cash Generation (TTM)
-$3.2M
$387M
Cash Flow Margin
-73.5%
24.8%
Net Cash / Leverage
$1.1M Net Cash
$59M Net Cash
Dividend Yield
None (0.00%)
None (0.00%)
5. Options & Positioning
LNTH
Options Structure Phase
UNCLASSIFIED
CONSOLIDATION
Current IV / %ile
N/A (N/A)
7.2% (4th %ile)
Put/Call OI Skew
N/A
0.87x (Balanced)
OBV Trend / Tech Phase
NEUTRAL · Markdown
DISTRIBUTION · Neutral
6. R&D & Supply-Chain Moat
LNTH
OpEx & R&D Intensity
N/A
44.4% of Rev ($694M)
90D R&D Disclosures
0 papers
0 papers
Competitive Moat
Cyclical / Execution-Driven Positioning
Scale & Operating Efficiency Moat
Supply-Chain Role
Medical Devices Operator
Drug Manufacturers - Specialty & Generic Operator
Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table
Core Matrix Wins: BMRA (1) vs LNTH (9)| Institutional Metric | BMRA | LNTH | Criterion | Row Edge |
|---|---|---|---|---|
| Market Capitalization | $6.0M | $6.6B | LNTH | |
| Trailing P/E Ratio | N/M | 25.3x | LNTH | |
| Forward P/E Ratio | N/M | 15.4x | LNTH | |
| Revenue Growth (YoY) | -8.3% | +1.5% | LNTH | |
| Operating Margin (TTM) | -125.2% | 16.9% | LNTH | |
| Net Profit Margin | -115.5% | 17.3% | LNTH | |
| Return on Equity (ROE) | -113.8% | 21.8% | LNTH | |
| 52-Week Range Position | 5% ($1–$3) | 83% ($51–$112) | LNTH | |
| Beta / 30D Volatility | 0.67β · 62% Vol | 0.45β · 5% Vol | LNTH | |
| Unified Institutional Score | 44.5 / 100 (HOLD) | 43.5 / 100 (HOLD) | BMRA | |
| Trailing 12M Revenue (USD) | $4.3M | $1.56B | Scale | |
| Gross Profit Margin (TTM) | 0.9% | 61.3% | Quality | |
| PEG Ratio & EV / Revenue | N/M PEG · 1.1x EV/Rev | 0.61x PEG · 4.2x EV/Rev | Valuation | |
| Cash Flow & Balance Sheet | -$3.2M ($1.1M Net Cash) | $387M ($59M Net Cash) | Solvency |
Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)
1M Horizon
LNTH +28.54 pp
3M Horizon
LNTH +16.48 pp
6M Horizon
LNTH +48.81 pp
1Y Horizon
LNTH +137.14 pp
Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)
| Period | BMRA Revenue | LNTH Revenue | BMRA Op. Margin | LNTH Op. Margin | Margin Leader |
|---|---|---|---|---|---|
| FY2019 | $10M | $350M | -46.4% | 14.9% | LNTH |
| FY2020 | $10M | $340M | -41.0% | -1.2% | LNTH |
| FY2021 | $10M | $430M | -104.2% | -14.3% | LNTH |
| FY2022 | $20M | $940M | -24.0% | 3.9% | LNTH |
| FY2023 | $10M | $1.30B | -135.3% | 28.1% | LNTH |
| FY2024 | $10M | $1.53B | -117.6% | 29.8% | LNTH |
| FY2025 | $10M | $1.54B | -96.7% | 20.2% | LNTH |
| FY2026 | $0M | N/A | -119.5% | N/A | BMRA |
Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor
Live Options Phase Tracker
BMRA
UNCLASSIFIED
Current IV
N/A
IV Percentile
N/A
Put/Call OI Skew
N/A
IV Regime
Unclassified
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
Net Delta Signal
NEUTRAL
OBV Flow
NEUTRAL
Exact BMRA Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro.
Unlock 14-Day Free Trial →
LNTH
CONSOLIDATION
Current IV
7.2%
IV Percentile
4th %ile
Put/Call OI Skew
0.87x (Balanced)
IV Regime
Compressed (<25th %ile)
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
Net Delta Signal
BULLISH
OBV Flow
DISTRIBUTION
Exact LNTH Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro.
Unlock 14-Day Free Trial →
Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity
Corporate R&D & Foundry Leaderboard
BMRA Moat Profile
Cyclical / Execution-Driven Positioning
Medical Devices Operator
OpEx & R&D Reinvestment
N/A
90D Engineering Disclosures
0 Published
LNTH Moat Profile
Scale & Operating Efficiency Moat
Drug Manufacturers - Specialty & Generic Operator
OpEx & R&D Reinvestment
44.4% of Rev ($694M)
90D Engineering Disclosures
0 Published
Investor FAQ BMRA vs LNTH Key Questions & Quantitative Answers
As of Nov 16, 2026, Lantheus Holdings, Inc (LNTH) is the stronger overall head-to-head candidate over Biomerica Inc (BMRA) in the Tradestie Institutional Equity Comparison Engine, winning 9–1 core matrix metrics and 6–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). BMRA carries a Unified Composite Score of 44.5/100 (HOLD) at $1.36 (N/M Forward P/E, -125.2% operating margin), whereas LNTH carries 43.5/100 (HOLD) at $101.75 (15.4x Forward P/E, 16.9% operating margin). Composite vs. Pillar Nuance: While BMRA currently prints a higher short-term Unified Composite Score (44.5/100 HOLD vs. LNTH 43.5/100 HOLD), LNTH captures the overall institutional head-to-head verdict (9–1 matrix metrics and 6–0 across the 6 pillars) due to superior fundamental profitability (16.9% vs. -125.2% operating margin) and revenue trajectory (+1.5% vs. -8.3% YoY). Technical & Structure Timing Caution: BMRA is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 28.0); meanwhile LNTH trades in a Neutral technical trend (CONSOLIDATION options phase, RSI 65.8). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
LNTH leads the Growth & Scale pillar: BMRA posts -8.3% YoY revenue growth and +0.0% YoY earnings growth on $4.3M TTM revenue (0.9% gross margin, -125.2% operating margin), compared with LNTH at +1.5% YoY revenue growth and -19.5% YoY earnings growth on $1.56B TTM revenue (61.3% gross margin, 16.9% operating margin). Across the 8-period historical trajectory (FY2019 to FY2026), BMRA cumulative revenue shifted +0.0% while LNTH shifted +340.0%. In operating R&D and SG&A reinvestment, BMRA deploys N/A (0 90-day corporate R&D disclosures) versus 44.4% of Rev ($694M) (0 disclosures) for LNTH.
LNTH screens cheaper on headline valuation multiples. BMRA trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 1.1x EV/Revenue (-73.5% FCF margin), whereas LNTH trades at 15.4x Forward P/E, 25.3x Trailing P/E, 0.61x PEG, and 4.2x EV/Revenue (24.8% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against BMRA (-113.8% ROE) versus LNTH (21.8% ROE) capital efficiency.
In options market volatility and institutional positioning, BMRA carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.67β · 62% Vol realized risk). By comparison, LNTH carries 7.2% implied volatility (4th %ile, Compressed (<25th %ile)), a 0.87x (Balanced) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a CONSOLIDATION options structure phase (0.45β · 5% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Launch Custom Ticker Comparison →
LNTH vs BMRA · Reverse Pair
LNTH vs MEDP
· Sector Peer
LNTH vs LIVN
· Sector Peer
LNTH vs KRYS
· Sector Peer
INTC vs AMD
· x86 & Data Center CPU
NVDA vs AMD
· AI Accelerators
TSM vs ASML
· Foundry & Lithography
MSFT vs GOOGL
· Hyperscale Cloud & AI
AAPL vs META
· Consumer Ecosystem
LLY vs NVO
· GLP-1 Biopharma
AVGO vs MRVL
· Custom ASIC & Networking